Correction to Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1,Open‐Label, Single‐Dose, Parallel‐Group Study
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Tags: Correction Source Type: research
More News: Drugs & Pharmacology | Study